Synchronized determination of fingolimod and its primary metabolite fingolimod phosphate in Whole blood: Bio-equivalence approach

نویسندگان
doi
10.48309/jmpcr.2026.509140.1615
چکیده

A novel tandem mass spectrometry (LC-MS/MS) bio-analytical method was developed and validated for the synchronized quantitation of fingolimod (FIN) and its active metabolite, fingolimod-phosphate (FPH), in human whole blood using a unified sample preparation protocol. This method was successfully applied in a bio-equivalence study comparing a 0.5 mg test capsule to the reference product, Gilenya™, in twenty-eight healthy male subjects under fasting conditions. The study employed a randomized, single-dose, two-period, two-treatment, two-sequence crossover design with a seven-week washout period. FIN and its internal standard (IS) were extracted using liquid-liquid extraction, while FPH was isolated from the residual blood via protein precipitation. Quantitative analysis of both analytes was performed using positive electrospray ionization in multiple reaction monitoring mode (+ESI-MRM), with ion transitions of m/z 388.2 → 255.3 (IS: 392.12 → 259.2) for FIN, and m/z 308.4 → 255.3 (IS: 312.4 → 259.3) for FPH. The method was validated over dynamic calibration ranges of 10-800 pg/mL for FIN and 50-5000 pg/mL for FPH, meeting all acceptance criteria of EMEA bioanalytical method validation guidelines. Pharmacokinetic parameters including C max and AUC 0t were determined for both FIN and FPH and compared between the test and reference formulations. The results confirmed that both products are bio-equivalent.